ELISA/assay

Mouse Bile acid receptor (NR1H4) ELISA Kit

MBS7220213

48-Strip-Wells

440 USD

ELISA Kit

Mouse Bile acid receptor (NR1H4) ELISA Kit

[Bile acid receptor (NR1H4)]

[bile acid receptor isoform 3; Bile acid receptor; bile acid receptor; farnesol receptor HRR-1; RXR-interacting protein 14; farnesoid X nuclear receptor; farnesoid X-activated receptor; retinoid X receptor-interacting protein 14; nuclear receptor subfamily 1, group H, member 4; Farnesoid X-activated receptor; Farnesol receptor HRR-1; Nuclear receptor subfamily 1 group H member 4; Retinoid X receptor-interacting protein 14; RXR-interacting protein 14]

[NR1H4]

[NR1H4; NR1H4; BAR; FXR; HRR1; HRR-1; RIP14; BAR; FXR; HRR1; RIP14; RXR-interacting protein 14]

NR1H4_HUMAN

Mouse

This assay has high sensitivity and excellent specificity for detection of NPHN. No significant cross-reactivity or interference between NPHN and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between NPHN and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Typical Testing Data/Standard Curve (for reference only)

Samples: Serum, Plasma, Cell Culture Supernatants, Body Fluid And Tissue Homogenate. Assay Type: Quantitative Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This NPHN ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Mouse NPHN. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: NPHN ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-NPHN antibody and an NPHN-HRP conjugate. The assay sample and buffer are incubated together with NPHN-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the NPHN concentration since NPHN from samples and NPHN-HRP conjugate compete for the anti-NPHN antibody binding site. Since the number of sites is limited, as more sites are occupied by NPHN from the sample, fewer sites are left to bind NPHN-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The NPHN concentration in each sample is interpolated from this standard curve.

332801067

NP_001193922.1

NM_001206993.1

48,795 Da

Bile Acid And Bile Salt Metabolism Pathway (106144); Bile Secretion Pathway (193146); Bile Secretion Pathway (193095); Biological Oxidations Pathway (105698); Cytochrome P450 - Arranged By Substrate Type Pathway (105700); Drug Induction Of Bile Acid Pathway (698755); Endogenous Sterols Pathway (105701); Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway (160977); Gene Expression Pathway (105937); Generic Transcription Pathway (105938)

This gene encodes a ligand-activated transcription factor, which shares structural features in common with nuclear hormone receptor family, such as a DNA-binding domain that targets the receptor to specific DNA sequences, and a ligand-binding domain, which interacts directly with the ligand and contains a ligand-dependent transcriptional activation domain. This protein functions as a receptor for bile acids, and when bound to bile acids, regulates the expression of genes involved in bile acid synthesis and transport. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2011]

NR1H4: Ligand-activated transcription factor. Receptor for bile acids such as chenodeoxycholic acid, lithocholic acid and deoxycholic acid. Represses the transcription of the cholesterol 7-alpha-hydroxylase gene (CYP7A1) through the induction of NR0B2 or FGF19 expression, via two distinct mechanisms. Activates the intestinal bile acid-binding protein (IBABP). Activates the transcription of bile salt export pump ABCB11 by directly recruiting histone methyltransferase CARM1 to this locus. Heterodimer of NR1H4 and RXR. After activation by agonist binding, interacts with a coactivator, NCOA1 or NCOA2. Interacts with CARM1 and SMARD1. Belongs to the nuclear hormone receptor family. NR1 subfamily. 4 isoforms of the human protein are produced by alternative splicing. Protein type: Nuclear receptor; DNA-binding. Chromosomal Location of Human Ortholog: 12q23.1. Cellular Component: nucleoplasm. Molecular Function: RNA polymerase II transcription factor activity, enhancer binding; ligand-dependent nuclear receptor binding; ligand-dependent nuclear receptor activity; zinc ion binding; bile acid binding; transcription coactivator activity; peptide binding; retinoid X receptor binding; protein binding; sequence-specific DNA binding; double-stranded DNA binding; steroid hormone receptor activity; thyroid hormone receptor activity; transcription factor activity; transcription corepressor activity. Biological Process: transcription initiation from RNA polymerase II promoter; intracellular receptor-mediated signaling pathway; gut development; bile acid metabolic process; response to glucose stimulus; gene expression; regulation of carbohydrate metabolic process; positive regulation of transcription from RNA polymerase II promoter; steroid hormone mediated signaling; response to lipopolysaccharide; negative regulation of transcription from RNA polymerase II promoter; signal transduction

48-Strip-Wells

440 USD

96-Strip-Wells

640

5x96-Strip-Wells

2895

10x96-Strip-Wells

5415